Nature Biotechnology is a monthly journal publishing new concepts in biological technology of relevance to bioengineering, medicine, energy, agriculture, food and the environment. It has a magazine covering the commercial, political, ethical, legal and societal aspects of this research. http://feeds.nature.com/nbt/rss/current Nature Publishing Group en © 2026 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Nature Biotechnology © 2026 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. permissions@nature.com https://www.nature.com/uploads/product/nbt/rss.png http://feeds.nature.com/nbt/rss/current https://www.nature.com/articles/s41587-026-03319-6 Nature Biotechnology, Published online: 17 September 2026; doi:10.1038/s41587-026-03319-6

While technologies for smaller gene edits, such as base editing, have already entered clinical trials, larger gene cargoes face different challenges, including low editing efficiencies, delivery vehicle size constraints, and possible immunogenicity. Programmable genome engineering systems using recombinases; transposases, including CRISPR-associated transposases (CASTs); genome writing systems; and retrotransposons promise different avenues for therapy, but each system has unique limitations. What are the most promising strategies to further develop these technologies, and which parameters need to be further improved to make them efficient and safe for therapy? We asked three experts in the field to share their thoughts on the challenges and opportunities.]]> Alexandra Despang doi:10.1038/s41587-026-03319-6 Nature Biotechnology, Published online: 2026-09-17; | doi:10.1038/s41587-026-03319-6 2026-09-17 Nature Biotechnology 10.1038/s41587-026-03319-6 https://www.nature.com/articles/s41587-026-03319-6 https://www.nature.com/articles/s41587-026-03333-8 Nature Biotechnology, Published online: 16 September 2026; doi:10.1038/s41587-026-03333-8

A breast cancer drug linked with a test to detect ESR1 mutations in circulating tumor DNA is one of a wave of new drugs developed to tackle resistance to estrogen-receptor-targeted therapies.]]> Charlotte Harrison doi:10.1038/s41587-026-03333-8 Nature Biotechnology, Published online: 2026-09-16; | doi:10.1038/s41587-026-03333-8 2026-09-16 Nature Biotechnology 10.1038/s41587-026-03333-8 https://www.nature.com/articles/s41587-026-03333-8 https://www.nature.com/articles/s41587-026-03322-x Nature Biotechnology, Published online: 15 September 2026; doi:10.1038/s41587-026-03322-x

A versatile nanopore sensor, created by modifying a bacterial porin, enables the simultaneous identification of amino acids, nucleoside monophosphates, saccharides and peptides. Coupled with machine learning, it achieves 98.7% classification accuracy and enables the compositional analysis of native glycopeptides.]]> doi:10.1038/s41587-026-03322-x Nature Biotechnology, Published online: 2026-09-15; | doi:10.1038/s41587-026-03322-x 2026-09-15 Nature Biotechnology 10.1038/s41587-026-03322-x https://www.nature.com/articles/s41587-026-03322-x https://www.nature.com/articles/s41587-026-03314-x Nature Biotechnology, Published online: 15 September 2026; doi:10.1038/s41587-026-03314-x

China’s Decree 818 aims to bring hospital-based cell, gene and individualized therapies into the clinic safely. Its success will depend on whether it is consistently applied and whether adverse outcomes are reported, keeping patient safety at the forefront and holding institutions accountable for the results.]]> Jianqiang Wu doi:10.1038/s41587-026-03314-x Nature Biotechnology, Published online: 2026-09-15; | doi:10.1038/s41587-026-03314-x 2026-09-15 Nature Biotechnology 10.1038/s41587-026-03314-x https://www.nature.com/articles/s41587-026-03314-x https://www.nature.com/articles/s41587-026-03308-9 Nature Biotechnology, Published online: 14 September 2026; doi:10.1038/s41587-026-03308-9

Modified nanopore simultaneously identifies diverse biomolecules and their modifications.]]> Lang YaoZixuan WangJialu ChenWen SunKefan WangYunqi XiaoHanhan ZhangWenzheng LiYifan WangLulu ZhaoXinyi DaiLu QianPanke ZhangShuo Huang doi:10.1038/s41587-026-03308-9 Nature Biotechnology, Published online: 2026-09-14; | doi:10.1038/s41587-026-03308-9 2026-09-14 Nature Biotechnology 10.1038/s41587-026-03308-9 https://www.nature.com/articles/s41587-026-03308-9 https://www.nature.com/articles/s41587-026-03312-z Nature Biotechnology, Published online: 10 September 2026; doi:10.1038/s41587-026-03312-z

Biomimetic cells for studying T cell mechanotransduction]]> Dario Ummarino doi:10.1038/s41587-026-03312-z Nature Biotechnology, Published online: 2026-09-10; | doi:10.1038/s41587-026-03312-z 2026-09-10 Nature Biotechnology 10.1038/s41587-026-03312-z https://www.nature.com/articles/s41587-026-03312-z https://www.nature.com/articles/s41587-026-03289-9 Nature Biotechnology, Published online: 10 September 2026; doi:10.1038/s41587-026-03289-9

Recent patents relating to systems, methods and compositions for use in synthetic biology.]]> doi:10.1038/s41587-026-03289-9 Nature Biotechnology, Published online: 2026-09-10; | doi:10.1038/s41587-026-03289-9 2026-09-10 Nature Biotechnology 10.1038/s41587-026-03289-9 https://www.nature.com/articles/s41587-026-03289-9 https://www.nature.com/articles/s41587-026-03313-y Nature Biotechnology, Published online: 10 September 2026; doi:10.1038/s41587-026-03313-y

Moderna flu vaccine wins FDA approval]]> doi:10.1038/s41587-026-03313-y Nature Biotechnology, Published online: 2026-09-10; | doi:10.1038/s41587-026-03313-y 2026-09-10 Nature Biotechnology 10.1038/s41587-026-03313-y https://www.nature.com/articles/s41587-026-03313-y